Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer-Reference-Cited by-同舟云学术

Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer

Published:2020-07 Issue: Volume:145 Page:1-9
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Lin Yen-Ting,Tsai Tzu-Hsiu,Wu Shang-Gin,Liu Yi-Nan,Yu Chong-Jen,Shih Jin-Yuan

Funder

New Century Health Care Promotion Foundation, Taiwan

National Taiwan University Hospital, Taiwan

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference36 articles.

1. Precision management of advanced non-small cell lung cancer;Yang;Annu. Rev. Med.,2020

2. Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern;Wu;Oncologist,2008

3. Complex mutations in the epidermal growth factor receptor gene in non-small cell lung cancer;Hata;J. Thorac. Oncol.,2010

4. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer;Wu;Clin. Cancer Res.,2011

5. Uncommon EGFR mutations in advanced non-small cell lung cancer;O’Kane;Lung Cancer.,2017

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Treatment Patterns, Health Outcomes, and Healthcare Resource Use in Advanced Common EGFR-Positive Non-Small Cell Lung Cancer Patients Treated with Osimertinib in Alberta;Current Oncology;2024-07-31

2. Targeting HER3 to overcome EGFR TKI resistance in NSCLC;Frontiers in Immunology;2024-01-04

3. Tumor-associated Macrophages Mediate Gefitinib Resistance in Lung Cancer through HGF/c-met Signaling Pathway;Anti-Cancer Agents in Medicinal Chemistry;2024-01

4. A Durable Response to Osimertinib in an Elderly Patient With EGFR T790M Positive Metastatic Non–Small-Cell Lung Cancer After Progression on Erlotinib;American Journal of Therapeutics;2023-09

5. Association of PD‐L1 tumor proportion score ≥20% with early resistance to osimertinib in patients with EGFR‐mutated NSCLC;Cancer Medicine;2023-08-07